Scientists have gathered more details about the DNA of Icelanders as compared to any other nation on earth. Genomes of more than 1 in every 100 people in the country have been sequenced by scientists at Amgen's DeCode Genetics.

Nordic quest of the company follows a theory that mutant genes could reveal the secrets of future medicine by finding uncommon human outliers whose DNA protects them against ailments that others suffer.

According to the researchers, this is a strategy that's already provided one future blockbuster. The company said that wide-scale genome sequencing is going to produce numerous more drug targets. Genetic variations have been found by the researchers. According to the researchers, the found genetic variations boost the risks of Alzheimer's disease, liver and thyroid ailments and an erratic, potentially deadly heart rate identified as a trial fibrillation.

California-based Biotechnology Company, Amgen, said the Thousand Oaks have given 415 million for Reykjavik, Iceland-based DeCode two years ago. At present, the company is examining its research projects against DeCode's database to ensure its medications are hitting the right target. According to Stefansson, an Icelander himself, the company has abandoned programs and sped up others based on the findings.

"The next big initiative in health care in the western parts of the world is going to come through the use of genetics. You can basically trace all human diversity, the risk of disease and the response to treatment", said Stefansson. He also said that their organization provides answers to difficult questions about the cause of disease.

Abraham A. Palmer, associate professor of human genetics at the University of Chicago, said that the paper that was published on Wednesday tells how the study of genetics is changing.